Cardiovascular Risk In Children With Hereditary Rickets

X-linked hypophosphatemia (XLH) is the most prevalent form of hereditary rickets. It is caused by loss-of-function mutations in the phosphate-regulating Endopeptidase Homolog X-linked (PHEX) gene, which results in elevated circulating levels of fibroblast growth factor 23 (FGF23), which, in turn, gives rise to a high waste of phosphate in urine, low serum phosphate concentration, and reduced production of 1,25 dihydroxy vitamin D [1,25(OH)2 vitamin D], the active form of vitamin D in our body.

XLH is transmitted following a dominant inheritance linked to chromosome X. Thus, mothers with XLH transmit the disease to 50% of their offspring, and fathers with XLH transmit the disease to all their daughters and none of their sons. However, it is of note that in the majority of cases, the PHEX gene mutations appear de novo, that is, the patient has the disease, but the parents are healthy. It is not known why new mutations arise.

Though the severity of clinical manifestations is highly variable, children with XLH characteristically present with vitamin D-resistant rickets (Figure 1) during infancy and develop shortening of lower extremities, bone deformities (Figure 2), and disharmonic growth failure.

Figure 1: Radiological widening of the wrist (metaphyseal cupping), due to the protrusion of bulky mass of cartilaginous cells in the zone of hypertrophy into the poorly mineralized metaphysis. Image courtesy of the authors.
Figure 2: X-ray of legs showing bowing of tibiae (the weight-bearing bones). Image courtesy of the authors.

Adults have reduced final height, leg bowing (Figure 3), and bones deficiently mineralized (osteomalacia) that may cause bone pain and muscular weakness. Dental abnormalities are frequently found in children and adults, and patients with XLH may also develop deafness and vertigo in the long term if the bones of the inner ear are involved.

Figure 3. Bowing of both legs – a classical sign of rickets. Image courtesy of the authors.

Maintained oral phosphate supplementation and administration of vitamin D derivatives ameliorate the manifestations of XLH, and this has been the basis of conventional, classic therapy of XLH. However, this combined treatment does not decrease the elevated FGF23 levels or antagonize other potential undesirable actions of FGF23. This is important because high FGF23 has been shown to induce left ventricular hypertrophy (enlargement of heart muscle cells),1 and it has been related with cardiac toxicity and the increased risk of death by cardiovascular complications in patients with chronic kidney disease.2 Thus, it could be hypothesized that patients with XLH, who keep elevated serum concentrations of FGF23 despite treatment, might develop cardiovascular damage, even in childhood.

To address this issue, we studied 24 children from 1 to 17 years of age (17 females) diagnosed with XLH and harboring PHEX mutations.3 Patients had been enrolled in the RenalTube database (www.renaltube.com) (Figure 4) and were receiving treatment with phosphate and vitamin D derivatives. In addition to biochemical parameters including determination of serum FGF23 values, we analyzed 24 hours of ambulatory blood pressure monitoring (ABPM), carotid vessel ultrasonography to assess intima-media thickness (broadness of vessel wall), and doppler echocardiography. By doing this, we wanted to find out whether these patients had signs of cardiovascular toxicity demonstrated by arterial hypertension, arteriosclerosis, and/or left ventricular hypertrophy.

Figure 4: Renal tube database – for the study of primary tubulopathies. Figure courtesy of the authors.

All but one patient had serum FGF23 concentrations above the normal reference values. Abnormally high carotid intima-media thickness and arterial hypertension were found in one case, but this finding was attributed to the marked obesity of this patient rather than XLH. Arterial hypertension was disclosed in two other children. The group’s mean left ventricular mass index (LVMI) measured by cardiac ultrasonography was 44.93± 19.18 g/m2.7, and four patients, in addition to the obese one, had values greater than 51 g/m2.7, a value considered to be indicative of left ventricular hypertrophy. There was no correlation between these echocardiographic parameters and serum FGF23 concentrations.

In summary, our results showed that XLH pediatric patients receiving conventional treatment have echocardiographic measurements of ventricular mass within normal reference values, but above the mean, and 18% have LVMI suggestive of left ventricular hypertrophy without correlation with serum FGF23 concentrations. This might indicate an increased risk of cardiovascular involvement in XLH since an early age.

These findings have important clinical implications and support the need for monitoring cardiovascular disease in the diagnosis and follow-up of patients with XLH. Moreover, the possibility of increased cardiovascular toxicity in XLH raises the issue of whether treatment with burosumab, a new monoclonal antibody against FGF23 shown to cause beneficial metabolic and clinical effects in XLH 4, might also be useful in preventing or reversing left ventricular hypertrophy in these patients.

Further research studies are necessary to clarify the risk of cardiovascular involvement in XLH and the actual pathogenic role of FGF23 as well as the potential positive consequences of burosumab treatment on this complication of XLH.

These findings are described in the article entitled Risk of Cardiovascular disease in patients with X linked Hypophosphataemia, recently published in the journal Pediatric Nephrology.

About The Author

R Balasubramanian

R. Balasubramanian is a medical student and researcher at the KLE Academy of Higher Education and Research's (KAHER's) Jawaharlal Nehru Medical College - Belagavi, Karnataka, India, and is also studying at the University of Ovideo.

Oláya Hernandez-Frías

Oláya Hernandez-Frías is a research scientist at the University of Ovideo.

HG
Helena Gil-Peña

Helena Gil-Peña is a research scientist at the Hospital Universitario Central de Asturias.

Fernando Santos

Fernando Santos is  the Professor & Chairman of Pediatrics at the Hospital Universitario Central de Asturias & University of Oviedo.

Speak Your Mind!

READ THIS NEXT

Metamorphic Electronics For 3D Acoustics

Recent advancement in the field of electronics has taken a shift to enable the realization of mechanical stretchable electronic products. Mechanical stretchability is key to produce electronic systems, which morph to take on new form factors. However, current strategies have some limitations. For example, wrapping of a standard PET bottle with electronics would greatly benefit […]

All You Need Is Clove: Sustainable Composites For Active Food Packaging

Unpackaging convenience food is one of the most routine, boring, and trivial activities in the West. The massive repetition during decades of this underestimated action has been the main “silent” source of plastic pollution in the environment. Plastics are ubiquitous materials due to their low cost, easy processability, and excellent physical properties. For instance, they […]

How To Predict Materials’ Lifetime For Solar Technologies

Global warming and climate change are probably the major challenges facing humanity today, which necessitates the reduction of the anthropogenic CO2 emissions into the atmosphere. In the context of increasing energy demand, renewable energies with a low carbon footprint have then to be developed, and among them, solar energy constitutes a viable option. This is […]

Domestic Energy Efficiency: What Can Policy Development Learn From Geography?

The amount of energy used in European homes for heating, cooling, and to power electrical appliances makes up a substantial part of energy consumption, accounting for over a quarter of energy demand in the European Union in 2015. Much of the stock of existing homes was built in the second half of the 20th century […]

How Sulfur Makes Its Way Into The Soil Of Forested Ecosystems

The term “acid rain” may sound like an old legend to most people. This environmental issue, which once seriously threatened the health of northeastern North-American forests, lakes, and rivers, has indeed partly been solved. The Clean Air Act, signed in 1970, introduced stricter regulations of sulfur emissions (the principal element responsible for acid rain) which […]

The Plan Of Four-Dimensional Regulation (4D Plan) For Cancer Patients: First Systematic Plan For Cancer Patients In The World

Cancer is still a global issue. Surgery, chemotherapy, radiotherapy, and present immune therapy do prolong the lives of cancer patients, but these cannot correct a disordered immune system, a result of cancer. Free radicals are often hazardous to patients and can damage all major components of cells, including DNA, proteins, and cell membranes. The damage […]

Will A “Grand Convergence In Global Health” Happen By 2035?

A major question for public health researchers worldwide is, despite considerable progress made in the health status of almost all regions of the world, will a “Grand Convergence” in health be achieved globally by 2035? Recently, researchers from Jawaharlal Nehru University, New Delhi, have expressed their apprehension regarding this vision. To further the vision of […]